Drugs / GT719
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT07389499 | May 2026 → Jun 2028 expected | IgA glomerulonephritis, anti-neutrophil cytoplasmic antibody-associated vasculitis, membranous glomerulonephritis, proliferative glomerulonephritis | Grit Biotechnology | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07132112 | Oct 2025 → Aug 2028 expected | autoimmune disease | Grit Biotechnology | Recruiting | No outcome recorded |
| Phase 0 | NCT07122076 | Aug 2025 → Aug 2028 expected | autoimmune disease | Grit Biotechnology | Recruiting | No outcome recorded |
| Phase 0 | NCT07131254 | Mar 2025 → Dec 2027 expected | hematopoietic and lymphoid cell neoplasm | Grit Biotechnology | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07021209 | Jan 2025 → Jan 2028 expected | autoimmune disorder of the nervous system | Grit Biotechnology | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06948981 | Apr 2025 → Apr 2028 expected | hematopoietic and lymphoid cell neoplasm | Grit Biotechnology | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GT719 | “GT719 universal cell injection” NCT07389499 ↗ |
| Modality | Cell therapy | “GT719 Universal Cell Injection” NCT07131254 ↗ |
| Target | CD19 | “CD19-targeted iNKT cells” NCT07389499 ↗ |